Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 4/20 | 0.58 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 8/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 1/20 | 0.40 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907584 | 0.87 | UGCG (0.67) | UGCGSCN8ASCN10AAXLMET | |
| SCHEMBL29907618 | 0.86 | UGCG (0.62) | UGCGAXLGPR6MRGPRX1 | |
| SCHEMBL29907648 | 0.83 | UGCG (0.67) | UGCGAXLMETRIPK3RIPK2 | |
| SCHEMBL24464251 | 0.83 | UGCG (0.60) | UGCGAXLMETRIPK3RIPK2 | |
| SCHEMBL29907411 | 0.83 | UGCG (0.60) | UGCGAXLMETRIPK3RIPK2 | |
| SCHEMBL29907685 | 0.83 | UGCG (0.69) | UGCGAXLMETRIPK3MRGPRX1 | |
| SCHEMBL29907613 | 0.83 | UGCG (0.83) | UGCGAXLMETRIPK3RIPK2 | |
| SCHEMBL29907452 | 0.83 | UGCG (0.51) | UGCGAXLMETRIPK3RIPK2 | |
| SCHEMBL24464215 | 0.82 | UGCG (0.55) | UGCGAXLMETRIPK3RIPK2 | |
| SCHEMBL24464284 | 0.82 | UGCG (0.60) | UGCGAXLMETRIPK3MRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885SCN8A 1938/4885SCN10A 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.